Page 1 of 2

Ajanta House Charkop, Kandivli West, Mumbai 400 067 India

T +91 22 6606 1000 F +91 22 6606 1200 E info@ajantapharma.com W www.ajantapharma.com

Corporate Identity Number – L24230MH1979PLC022059

Press Release

Q2 Income from Operations at Rs. 540 cr., PAT at Rs. 132 cr. (2nd Quarter & Half year, FY 2018 Consolidated Results)

Mumbai, 31st October, 2017: Ajanta Pharma Ltd. a specialty pharmaceutical formulation company reported today its performance for the 2nd quarter & half year ended 30th September 2017. Q2 FY 2018 performance highlights (Consolidated, compared to Q2 FY 2017)

Income from operations at Rs. 540 cr. against Rs. 516 cr., up 5%.

EBITDA at Rs. 184 cr. against Rs. 183 cr., EBITDA at 34% of revenue.

Profit after tax at Rs. 132 cr., against Rs. 131 cr., PAT at 24% of revenue.

Total comprehensive income at Rs. 134 cr. against Rs. 125 cr. up 7%.

H1 FY 2018 performance highlights (Consolidated, compared to H1 FY 2017)

Income from operations at Rs. 1014 cr. against Rs. 992 cr., up 2%.

EBITDA at Rs. 314 cr. against Rs. 349 cr., down 10%, EBITDA at 31% of revenue.

Profit after tax at Rs. 227 cr., against Rs. 250 cr., down 9%, PAT at 22% of revenue.

Total comprehensive income at Rs. 230 cr. against Rs. 250 cr. down 8%.

Commenting on the results, Mr. Rajesh Agrawal, Jt. Managing Director said:

“Our India business has performed satisfactorily and we are seeing the recovery post GST

reform. Similarly, emerging markets have posted satisfactory growth. In US, we are seeing

the effect of the customer consolidation resulting in price pressure. With launch of newer

products, we are hopeful to improve the performance in US in coming quarters.”

India

For Q2 FY 2018, India’s branded generic sales (excluding institution) was Rs. 172 cr. posting

growth of 12% and total India sales (including institution), was Rs. 178 cr., growth of 13%.

For H1 FY 2018, India branded sales (excluding institution) was Rs. 307 cr. de-growth of 1%

and total India sales (including institution) was Rs. 321 cr., same level as last year.

As per IMS MAT September 2017, we have posted healthy growth of 16% in Cardiology

(segment growth of 6%), 16% in Ophthalmology (segment growth of 8%), 7% in Dermatology

(segment growth of 16%) and 10% in Pain Management (segment growth of 3%).

Exports

During Q2 FY 2018, export sales were Rs. 350 cr., posting growth of 2%. Africa contributed

Rs. 218 cr., growth of 25%, Asia contributed Rs. 104 cr., growth of 6% and US contributed Rs.

26 cr. de-growth of 63%.

Page 2 of 2

Ajanta House Charkop, Kandivli West, Mumbai 400 067 India

T +91 22 6606 1000 F +91 22 6606 1200 E info@ajantapharma.com W www.ajantapharma.com

Corporate Identity Number – L24230MH1979PLC022059

For H1 FY 2018, exports sales grew 5% with sale of Rs. 671 cr. Africa contributed Rs. 387 cr.

(growth of 5%), Asia contributed Rs. 200 cr. (growth of 5%) and US contributed Rs. 81 cr.

same level as last year.

In US, we received 3 ANDA final approvals, commercialized 2 products and filed 4 ANDAs

with US FDA during Q2 FY 2018. With this, company has 15 products commercialized out of

21 final ANDA approvals, has 2 tentative approvals and 16 ANDAs awaiting approval with US

FDA at the end of Q2 FY 2018. Company plans to file 12-15 ANDAs during this financial year.

R&D

During Q2 FY 2018, R&D expenses were Rs. 48 cr., 9% of operating revenue (Q2 FY 2017

Rs. 37 cr.). For H1 FY 2018, R&D expenses were Rs. 95 cr., 9% of operating revenue (H1 FY

2017 Rs. 69 cr.).

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having branded generic

business in India and emerging markets, generic business in US and institution business in

Africa. Many of company’s products are 1st to market and are leading in their sub-therapeutic

segments.

Company’s state of the art R&D centres for formulation development and API are located at

Mumbai, having a team of 850+ scientists. Company has 7 world class manufacturing facilities

located in India and Mauritius.

For last 5 years, company has posted healthy performance with its consolidated total income

growing at 21% CAGR and net profit at 46% CAGR.

For more details visit www.ajantapharma.com

For regular updates follow us on twitter– www.twitter.com/ajantapharmaltd

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 66061377 Email: rajeev.agarwal@ajantapharma.com

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331

Corporate Identity Number (CIN): L24230MH1979PLC022059

Safe Harbour Statement